SPOTLIGHT: Doubt cast on Fosamax link to jaw decay

A new study by a Harvard dental professor may cast doubt on some claims that Merck's osteoporosis drug Fosamax caused some patients' jawbones to decay. The study shows that IV forms of the drug may have contributed to jaw disorders, but oral forms--which are far more commonly prescribed--actually reduced that risk. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.